Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

221. Erbitux for Left Sided Metastatic Colorectal Cancer – Details

Erbitux for Left Sided Metastatic Colorectal Cancer – Details Erbitux for Left Sided Metastatic Colorectal Cancer – Details | CADTH.ca Find the information you need Erbitux for Left Sided Metastatic Colorectal Cancer – Details Erbitux for Left Sided Metastatic Colorectal Cancer – Details Project Number pCODR 10128 Brand Name Erbitux Generic Name Cetuximab Strength 2 mg/mL Tumour Type Gastrointestinal Indication Left Sided Metastatic Colorectal Cancer Funding Request For the first-line treatment (...) of RAS wild-type metastatic colorectalcarcinoma (mCRC) patients with left sided primary tumours Review Status File-Closed Not Submitted Clarification The submitter notified pCODR that they will not be filing the submission. Pre Noc Submission No NOC Date September 9, 2005 Manufacturer Eli Lilly Canada Inc. Submitter Eli Lilly Canada Inc. Submission Date (Target Date) Submission Type New Indication Prioritization Requested Stakeholder Input Deadline (target date based on target submission date

2017 CADTH - Pan Canadian Oncology Drug Review

222. Minimally invasive surgery for gastric gastrointestinal stromal tumors Full Text available with Trip Pro

Minimally invasive surgery for gastric gastrointestinal stromal tumors Minimally invasive surgery has been increasingly performed for gastric gastrointestinal stromal tumors (GIST). In this review we discuss and summarize the current evidence on minimally invasive surgery for gastric GISTs. Laparoscopic resection for gastric GIST has been consistently shown to be associated with superior perioperative outcomes with no compromise in oncological outcomes when compared to open resection (...) in numerous retrospective case-control studies. It has also been shown to be safe and feasible for large tumors or tumors located in unfavorable sites. However, to date, there remains a lack of level 1 evidence from prospective randomized control trials in support of laparoscopic resection.

2017 Translational gastroenterology and hepatology

223. Initial clinical experience using a novel Pd-103 surface applicator for the treatment of retroperitoneal and abdominal wall malignancies Full Text available with Trip Pro

Initial clinical experience using a novel Pd-103 surface applicator for the treatment of retroperitoneal and abdominal wall malignancies 29904748 2019 02 26 2452-1094 3 2 2018 Apr-Jun Advances in radiation oncology Adv Radiat Oncol Initial clinical experience using a novel Pd-103 surface applicator for the treatment of retroperitoneal and abdominal wall malignancies. 216-220 10.1016/j.adro.2017.11.005 Zhen Heming H Department of Radiation Oncology, Boston Medical Center, Boston, Massachusetts

2017 Advances in radiation oncology

224. Surgical treatment of gastrointestinal stromal tumors of the stomach: current status and future perspective Full Text available with Trip Pro

Surgical treatment of gastrointestinal stromal tumors of the stomach: current status and future perspective Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, with the majority found in the stomach. Surgical resection of the primary gastric GISTs with complete resection margin has been the forefront of curative treatment. The indications for surgical resection are usually related to symptomatic gastric GISTs at presentation. Primary (...) factors (size and mitotic index), patient factors (older age, male) and surgical factors (incomplete resection margin, tumor rupture or spillage) play an important role in stratifying the malignant potential risk of primary gastric GISTs and their chances of recurrence. The understanding of gene mutation driving the growth of GISTs and the discovery of tyrosine kinase inhibitors (TKIs) has altered the surgical management of advanced and metastatic GISTs. Multi-modal therapy incorporating the surgical

2017 Translational gastroenterology and hepatology

225. Experience with an abdominal compression band for radiotherapy of upper abdominal tumours Full Text available with Trip Pro

Experience with an abdominal compression band for radiotherapy of upper abdominal tumours Radiotherapy outcomes are influenced by treatment delivery geometric accuracy and organ-at-risk dose. The location of abdominal structures such as the liver, kidneys and tumour volumes can be strongly influenced by respiratory motion. This increases geometric uncertainty and dose to organs-at-risk. One common method of minimising respiratory motion is abdominal compression (AC).Fifteen patients being (...) treated for radiotherapy to upper abdominal tumours were analysed. Each patient underwent 2 four-dimensional computerised tomography (4D-CT) scans, one with and one without AC with a pneumatic compression belt. Liver and kidney positions were measured on the 4DCT scans at the peak inspiratory and expiratory respiratory phases. The patient received radiation therapy treatment planned on the CT data set with the technique (compression or no compression) that provided the least respiratory motion.There

2017 Journal of medical radiation sciences

226. Randomized clinical trial of laparoscopic ultrasonography before laparoscopic colorectal cancer resection (Abstract)

Randomized clinical trial of laparoscopic ultrasonography before laparoscopic colorectal cancer resection Intraoperative ultrasonography during open surgery for colorectal cancer may be useful for the detection of unrecognized liver metastases. Laparoscopic ultrasonography (LUS) for the detection of unrecognized liver metastasis has not been studied in a randomized trial. This RCT tested the hypothesis that LUS would change the TNM stage and treatment strategy.Patients with colorectal cancer (...) of colorectal cancer is not recommended. Registration number: NCT02079389 (http://www.clinicaltrials.gov).© 2017 BJS Society Ltd Published by John Wiley & Sons Ltd.

2017 EvidenceUpdates

227. Bevacizumab (Kyomarc) - for the treatment of cancer of the colon or rectum, breast cancer, non-small cell lung cancer (NSCLC), kidney cancer, cervical cancer, and cancer of the ovary, the fallopian tube, or the peritoneum.

Bevacizumab (Kyomarc) - for the treatment of cancer of the colon or rectum, breast cancer, non-small cell lung cancer (NSCLC), kidney cancer, cervical cancer, and cancer of the ovary, the fallopian tube, or the peritoneum.

2017 European Medicines Agency - EPARs

228. The proof is in the pudding: improving adenoma detection rates reduces interval colon cancer development Full Text available with Trip Pro

The proof is in the pudding: improving adenoma detection rates reduces interval colon cancer development 29264437 2018 11 13 2415-1289 2 2017 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol The proof is in the pudding: improving adenoma detection rates reduces interval colon cancer development. 99 10.21037/tgh.2017.11.10 Umar Sarah B SB Division of Gastroenterology and Hepatology, Mayo Clinic, Arizona, USA. Ramirez Francisco C FC Division of Gastroenterology

2017 Translational gastroenterology and hepatology

229. Colorectal Cancer Awareness: The Gastroenterology Resolution for the Future Full Text available with Trip Pro

Colorectal Cancer Awareness: The Gastroenterology Resolution for the Future 29662926 2018 11 14 2341-4545 25 2 2018 Mar GE Portuguese journal of gastroenterology GE Port J Gastroenterol Colorectal Cancer Awareness: The Gastroenterology Resolution for the Future. 55-56 10.1159/000481861 Oliveira Ferreira Alexandre A Gastroenterology Department, Hospital Beatriz Ângelo, Loures, Portugal. eng Editorial 2017 11 30 Switzerland GE Port J Gastroenterol 101685861 2387-1954 Adenoma Colorectal cancer (...) Screening 2017 09 21 2017 09 27 2018 4 18 6 0 2018 4 18 6 0 2018 4 18 6 1 ppublish 29662926 10.1159/000481861 pjg-0025-0055 PMC5892355 Int J Cancer. 2015 Mar 1;136(5):E359-86 25220842 Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001216 17253456 Gastroenterology. 2017 Jul;153(1):307-323 28600072 N Engl J Med. 2013 Sep 19;369(12):1095-105 24047059 JAMA. 2000 Oct 18;284(15):1954-61 11035892 N Engl J Med. 2014 Apr 3;370(14):1298-306 24693890

2017 GE Portuguese journal of gastroenterology

230. QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer Full Text available with Trip Pro

QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer A Quality-adjusted Time WIthout Symptoms of disease or Toxicity (QTWiST) analysis was carried out to assess quality-adjusted survival time in the RECOURSE trial of trifluridine/tipiracil versus placebo in pretreated metastatic colorectal cancer (mCRC).Duration of overall survival in the RECOURSE trial (n=798 patients) was partitioned into three discrete health states: toxicity (TOX), time without (...) . A sensitivity analysis using large variations in utility coefficients for TOX and REL produced a range of only approximately 0.5 months from minimum to maximum QTWiST.Quality-adjusted survival, as measured by QTWiST, shows clinically meaningful improvements in patients treated with trifluridine/tipiracil versus placebo in pretreated mCRC.

2017 ESMO open Controlled trial quality: uncertain

231. Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial Full Text available with Trip Pro

Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial In the pivotal phase III, randomised, double-blind, placebo-controlled RECOURSE study, treatment with trifluridine/tipiracil was well tolerated and associated with prolonged progression-free and overall survival in patients with metastatic colorectal cancer (mCRC). There was no formal analysis of quality of life (QoL) in RECOURSE. The aim of the present analysis was to assess proxies of QoL during

2017 ESMO open Controlled trial quality: predicted high

232. Novel Stool-Based Protein Biomarkers for Improved Colorectal Cancer Screening: A Case-Control Study. (Abstract)

Novel Stool-Based Protein Biomarkers for Improved Colorectal Cancer Screening: A Case-Control Study. The fecal immunochemical test (FIT) for detecting hemoglobin is used widely for noninvasive colorectal cancer (CRC) screening, but its sensitivity leaves room for improvement.To identify novel protein biomarkers in stool that outperform or complement hemoglobin in detecting CRC and advanced adenomas.Case-control study.Colonoscopy-controlled referral population from several centers.315 stool (...) samples from one series of 12 patients with CRC and 10 persons without colorectal neoplasia (control samples) and a second series of 81 patients with CRC, 40 with advanced adenomas, and 43 with nonadvanced adenomas, as well as 129 persons without colorectal neoplasia (control samples); 72 FIT samples from a third independent series of 14 patients with CRC, 16 with advanced adenomas, and 18 with nonadvanced adenomas, as well as 24 persons without colorectal neoplasia (control samples).Stool samples

2017 Annals of Internal Medicine

233. Pediatric gastrointestinal stromal tumors: a commentary on the value of referral clinics for rare pediatric tumors Full Text available with Trip Pro

Pediatric gastrointestinal stromal tumors: a commentary on the value of referral clinics for rare pediatric tumors 29264434 2018 11 13 2415-1289 2 2017 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Pediatric gastrointestinal stromal tumors: a commentary on the value of referral clinics for rare pediatric tumors. 96 10.21037/tgh.2017.11.01 Fernandez-Pineda Israel I Department of Surgery, St Jude Children's Research Hospital, Memphis, TN, USA. Rao Bhaskar N BN (...) 5:v98-102 20555113 Cancer. 2004 Jul 1;101(1):39-50 15221987 Ann Oncol. 2012 Oct;23 Suppl 7:vii49-55 22997454 Am J Surg Pathol. 2005 Oct;29(10):1373-81 16160481 Pediatr Blood Cancer. 2004 Feb;42(2):186-9 14752885 J Clin Oncol. 2017 Feb 10;35(5):523-528 28029307

2017 Translational gastroenterology and hepatology

234. Therapeutic strategies for wild-type gastrointestinal stromal tumor: is it different from KIT or PDGFRA-mutated GISTs? Full Text available with Trip Pro

Therapeutic strategies for wild-type gastrointestinal stromal tumor: is it different from KIT or PDGFRA-mutated GISTs? 29264430 2018 11 13 2415-1289 2 2017 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Therapeutic strategies for wild-type gastrointestinal stromal tumor: is it different from KIT or PDGFRA -mutated GISTs? 92 10.21037/tgh.2017.11.05 Nishida Toshirou T Department of Surgery, National Cancer Center Hospital, Tokyo, Japan. eng Editorial Comment 2017 11 16 (...) Oncol. 2012 Mar;13(3):265-74 22153892 Cancer Discov. 2013 Jun;3(6):648-57 23550148 J Clin Invest. 2013 Jan;123(1):340-7 23221341 Ann Oncol. 2014 Sep;25 Suppl 3:iii21-6 25210085 J Gastroenterol. 2016 Jun;51(6):571-8 26511941 JAMA Oncol. 2016 Jul 1;2(7):922-8 27011036 Gastric Cancer. 2016 Jan;19(1):3-14 26276366 Int J Clin Oncol. 2008 Oct;13(5):416-30 18946752 Oncotarget. 2013 Feb;4(2):310-5 23470635 J Natl Compr Canc Netw. 2010 Apr;8 Suppl 2:S1-41; quiz S42-4 20457867 Genes Chromosomes Cancer. 2015

2017 Translational gastroenterology and hepatology

235. Understanding the critical role for surgery in the management of wild-type gastrointestinal stromal tumor (GIST) Full Text available with Trip Pro

Understanding the critical role for surgery in the management of wild-type gastrointestinal stromal tumor (GIST) 29264429 2018 11 13 2415-1289 2 2017 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Understanding the critical role for surgery in the management of wild-type gastrointestinal stromal tumor (GIST). 91 10.21037/tgh.2017.11.03 Kim Bradford J BJ Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA. Kays Joshua K JK Department (...) 10 30 2017 11 06 2017 12 22 6 0 2017 12 22 6 0 2017 12 22 6 1 epublish 29264429 10.21037/tgh.2017.11.03 tgh-02-2017.11.03 PMC5723733 J Clin Oncol. 2006 Oct 10;24(29):4764-74 16954519 J Am Coll Surg. 2006 Apr;202(4):623-9 16571433 Cancer Res. 2007 Oct 1;67(19):9084-8 17909012 J Natl Compr Canc Netw. 2007 Jul;5 Suppl 2:S1-29; quiz S30 17624289 Surgery. 2015 Nov;158(5):1149-64 26243346 Hematol Oncol Clin North Am. 2009 Feb;23(1):15-34, vii 19248968 Lancet Oncol. 2012 Mar;13(3):265-74 22153892 EMBO J

2017 Translational gastroenterology and hepatology

236. Exploration of time points and cut-off values for early tumour shrinkage to predict survival outcomes of patients with metastatic colorectal cancer treated with first-line chemotherapy using a biexponential model for change in tumour size Full Text available with Trip Pro

Exploration of time points and cut-off values for early tumour shrinkage to predict survival outcomes of patients with metastatic colorectal cancer treated with first-line chemotherapy using a biexponential model for change in tumour size Several studies reported that early tumour shrinkage (ETS) was associated with overall survival in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy. However, appropriate time point and cut-off value for ETS remain unclear (...) because these varied in previous studies.We investigated patients with mCRC who received FOLFOX or FOLFIRI with/without molecular-targeted agents as first-line treatment between 2005 and 2014. Using a biexponential model for change in tumour size, a relative change in the sum of the longest diameters of target lesions from baseline was estimated at a certain time point in each individual patient. Associations of survival outcomes with ETS at various time points based on various cut-off values were

2017 ESMO open

237. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. Full Text available with Trip Pro

Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. An increased risk of lymphoma has been reported among patients receiving thiopurines for inflammatory bowel disease (IBD). The risk of lymphoma associated with anti-tumor necrosis factor (TNF) agents either alone or in combination with thiopurines is uncertain.To assess the risk of lymphoma associated with thiopurines and anti-TNF

2017 JAMA

238. Surgical management of adolescent and young adults with gastrointestinal stromal tumors: it is of value? Full Text available with Trip Pro

Surgical management of adolescent and young adults with gastrointestinal stromal tumors: it is of value? 29264424 2018 11 13 2415-1289 2 2017 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Surgical management of adolescent and young adults with gastrointestinal stromal tumors: it is of value? 86 10.21037/tgh.2017.10.05 Esposito Francis F Medical Oncology Service, Hospital Clínic Barcelona, Barcelona 08036, Spain. Maurel Joan J Medical Oncology Service, Hospital (...) Feb;21(2):403-8 19628568 Ann Surg. 2007 Mar;245(3):341-6 17435538 J Clin Oncol. 2005 Aug 20;23(24):5795-804 16110036 Science. 2003 Jan 31;299(5607):708-10 12522257 Ann Surg Oncol. 2007 Jan;14(1):14-24 17072676 Int J Cancer. 2005 Nov 1;117(2):316-25 15900603 Science. 1998 Jan 23;279(5350):577-80 9438854 Eur J Surg Oncol. 2014 Apr;40(4):412-9 24491288 J Clin Oncol. 2006 May 20;24(15):2325-31 16710031 Ann Surg Oncol. 2015 Sep;22(9):2948-57 25608769 Ann Surg Oncol. 2006 Dec;13(12):1596-603 16957966

2017 Translational gastroenterology and hepatology

239. Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours

these recommendations Current treatment for unresectable or metastatic gastrointestinal stromal tumours after disease progression on, or intolerance to, prior treatment with imatinib and sunitinib is best supportive care. The evidence shows that people having regorafenib have longer before their disease progresses compared with those having best supportive care. However there is some uncertainty around how long regorafenib increases the overall length of time people live compared with those on best supportive care (...) of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence. Clinical management Best supportiv Best supportive care is the most appropriate compar e care is the most appropriate comparator ator 3.1 The patient and clinical experts explained that gastrointestinal stromal tumours (GIST) are a rare disease that often takes years to diagnose because people have non-specific symptoms. The clinical expert advised that first-line treatment for metastatic GIST

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

240. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 t Full Text available with Trip Pro

Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 t In the phase 3 RADIANT-4 trial, everolimus increased progression-free survival compared with placebo in patients with advanced, progressive, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (NETs). We now (...) of three) by an interactive voice response system to receive oral everolimus (10 mg per day) or placebo, both with best supportive care, with stratification by tumour origin, WHO performance status, and previous somatostatin analogue treatment. HRQOL was assessed with the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire at baseline (visit 2, day 1), every 8 weeks (± 1 week) during the study for the first 12 months after randomisation, and every 12 weeks thereafter until study drug

2017 EvidenceUpdates